China’s biopharma sector enters ‘Innovation 2.0’ era
Image created with Gemini
Western drug executives long treated China as little more than a sales target. Think more than a billion potential customers, a gold mine for revenue, but nothing special in terms of fresh ideas. Lately, that thinking has changed fast.
China now ranks as the world’s second-biggest pharmaceutical market. The country’s sales hit $112.8 billion in 2024, per IQVIA data. It’s also the second-largest producer of new molecular entities. Those grabbed 18% of global first launches that year, according to Clarivate’s most recent report.
Clarivate calls this move from “Innovation 1.0” to “Innovation 2.0.” The old phase meant quick growth bankrolled by easy money. Now the system has grown up. Chinese firms are now leading on cutting-edge work that big global players scramble to buy.
Deal-making shows it best. Chinese companies licensed out assets worth $50 billion through August 2025. That’s already more than all of 2024. For global pharma, these deals cut costs. Upfront fees come in 60% to 70% below worldwide averages. Overall packages run 40% to 50% smaller. A few giants even flip those assets later for a profit.
Take the big one in May. Pfizer shelled out $1.25 billion upfront for worldwide rights, minus China, to 3SBio’s PD-1/VEGF bispecific antibody SSGJ-707. Total value: $6.2 billion. Biggest ever for a Chinese breakthrough. It points to wider trends. Interest in antibody-drug conjugates for HER2 and TROP2 has faded. Buyers now are eyeing bispecifics and small molecules, especially in GLP-1 and immuno-oncology.
Beyond licensing existing drug classes, Chinese companies are now pioneering foundational science. Targeted protein degradation, a platform capable of addressing previously “undruggable” protein targets, has become a particular strength. China now accounts for 38% of global TPD publications and 37% of patents. In 2024 alone, Chinese entities received 400 granted TPD patents compared with 187 for the United States. Approximately 30% of the 484 TPD agents currently in global development originate from Chinese companies, with more than 40 firms actively advancing PROTAC therapies.
“China’s biopharmaceutical innovation landscape has fundamentally matured from rapid expansion to sustainable, quality-focused development,” said Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership at Clarivate (p. 4). Henry Levy, President of Clarivate Life Sciences and Healthcare, framed the shift more directly: “The data clearly shows we’re entering an era where ‘Made in China’ pharmaceuticals will be synonymous with cutting-edge science and global impact” (p. 6).
Underpinning this shift is a regulatory environment that has moved from obstacle to accelerant. China has implemented what the report calls “end-to-end support for innovation,” spanning R&D through reimbursement. A new 30-day fast-track approval channel for clinical trials has shortened development timelines, while the Commercial Health Insurance Formulary for Innovative Drugs, launched in July 2025, allows certain high-value therapies to bypass the price-cut pressures associated with national reimbursement negotiations. For Class 1 innovative drugs approved domestically, the gap between NMPA approval and first global approval has narrowed to an average of 334 days. Some companies have begun filing first in China, ahead of traditional markets like Australia, Canada, Japan, or Europe.
None of this means the path forward is uncomplicated. Geopolitical friction, IP harmonization challenges, and the ongoing pressure of volume-based procurement remain live concerns. But Clarivate’s data suggest a structural shift: median R&D intensity among the top 20 Chinese innovators now sits at 22% of revenue, with some biotechs exceeding 40%, figures that approach or match global pharma benchmarks. For Western executives still thinking of China primarily as a market to sell into, the recalibration may already be overdue.
Filed Under: Drug Discovery
No Byline Policy
Editorial Guidelines
Corrections Policy
Source